Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a dismal response to single-use of immune checkpoint inhibitors (ICIs). ICIs combined with systemic therapy has shown efficacy and safety in various solid tumors. Nab-paclitaxel and gemcitabine (AG), as the standard...

Full description

Bibliographic Details
Main Authors: Lin Shui, Ke Cheng, Xiaofen Li, Pixian Shui, Xiaohan Zhou, Jian Li, Cheng Yi, Dan Cao
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Pancreatic ductal adenocarcinoma
PD-1 blockade
Combination therapy
Clinical protocol
Online Access:http://link.springer.com/article/10.1186/s12885-020-07126-3

Internet

http://link.springer.com/article/10.1186/s12885-020-07126-3

Similar Items